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ABSTRACT 
Nasopharyngeal carcinoma (NPC) is an EBV-associated cancer. We analysed Siah1 expression as 
well as LMP1 and HIF1α expression by immuno-histochemical staining in 74 NPC biopsy 
specimens and found that the expression of Siah1 was significantly correlated with advanced tumour 
status and stage. Moreover, Siah1-positive and HIF1α-positive cases had significantly worse 
prognoses. The expression score for LMP1 was remarkably correlated with that of Siah1, whereas 
there was little correlation between LMP1 expression and the other markers evaluated. This is the 
first study to evaluate the pattern and clinical significance of Siah1 and HIF1α expression in NPC, 
and such an evaluation is valuable for identifying those patients at a high risk for a poor prognosis. 
1. Introduction  
 
Nasopharyngeal carcinoma (NPC) typically manifests with clinically invasive and 
metastatic features [1]. Despite recent advances in radiation techniques and chemotherapy, local 
failure and distant metastasis remain poor survival in patients with advanced NPC [2].  
Tumour hypoxia is one of the most common phenomena in human solid cancers. Tumour 
hypoxia is known to contribute to resistance to chemotherapy and radiotherapy as well as the 
malignant tumour phenotype, involving increased invasiveness and poor prognosis [3, 4]. In 
particular, of the proteins associated with tumour hypoxia, hypoxia-inducible factor 1-alpha (HIF1α) 
is a key hypoxia regulatory molecule [5]. HIF1α plays a major role in the development of the tumour 
phenotype and influences tumour growth rate, angiogenesis, invasiveness, and metastasis [6, 7]. Hui 
et al. showed that the overexpression of HIF1α at the primary tumour was related to worse prognosis 
in patients with NPC [8]. Although the regulation of HIF1α is complicated, Nakayama et al. 
identified a novel mechanism in which seven-in-absentia homologue (Siah)-family proteins 
contribute to the stabilisation of HIF1α under hypoxic conditions [9]. Siah-family proteins are the 
human homologues of seven-in-absentia, a conserved RING finger E3 ubiquitin ligase and essential 
downstream component of the Drosophila Ras signaling pathway. Two homologues, Siah1 and 
Siah2, have been shown to be involved in the response to DNA damage, the hypoxic response, 
inflammation, and several oncogenic signals including those propagated by Ras and epidermal 
growth factor receptor (EGFR) [10-13]. To date, few studies have addressed the role of Siah 
expression in cancer, and there has been no consensus as to the biologic significance of such 
expression [14, 15]. Thus, Siah expression and its role in the molecular pathogenesis of cancer, 
including NPC, remain unknown.  
Recently, we demonstrated that Epstein-Barr virus (EBV)-associated latent membrane 
protein 1 (LMP1) increased the expression of HIF1α via the induction of Siah1 in human 
nasopharyngeal epithelial cells [16]. Moreover, EBV is closely related to the carcinogenesis of NPC 
[1]. Among EBV proteins, LMP1 is a principal oncogenic protein that can transform resting B 
lymphocytes [17]. In addition, we have shown that the expression of LMP1 is responsible for the 
highly metastatic properties of NPC [17-19]. Therefore, we studied the expression of Siah1, HIF1α, 
and LMP1 in NPC biopsy specimens. The objective of our current study was to evaluate the 
association between Siah1, HIF1α, and LMP1 expression and the clinicopathological factors present 
in patients with NPC. 
 
2. Materials and methods 
 
2.1. Patients 
We obtained 74 tumour specimens from patients with NPC who had been diagnosed at the 
Division of Otolaryngology at Kanazawa University Hospital as well as other branch hospitals 
between May 1998 and December 2009. The characteristics of these patients are shown in Table 1. 
Clinical status was determined according to the 1997 UICC/AJCC staging system [20].  
Of the 74 patients, 59 patients received radiotherapy with cisplatin-based concurrent 
chemotherapy. Seven patients received radiotherapy due to increased age (>70 years) or renal 
dysfunction. According to the change of treatment protocol from 2005, 8 patients received 
alternating cisplatin-based chemo-radiotherapy, as described elsewhere [21]. The accumulated dose 
of radiation to the nasopharynx was 70-77 Gy in all cases, and the dose to the neck was 40-70 Gy. 
The median time of follow-up was 3.77 years (range 0.12-11.38 years). The survival period was 
calculated according to the date of initial treatment, and 29 of the patients studied were alive at the 
end of December 2009. 
 
2.2. Immunohistochemical analysis of NPC tissues 
Primary NPC paraffin-embedded specimens were used for the immunohistochemical 
analysis of Siah1, HIF1α, and LMP1 expression. Three-micrometre-thick sections were prepared 
from each block of tissue embedded in paraffin. Deparaffinised sections were treated with 3% 
hydrogen peroxide for 10 minutes to inactivate endogenous peroxidase activity. The sections were 
incubated with protein blocker (Dako, Glostrup, Denmark) for 20 minutes and incubated at 4°C 
overnight with rabbit anti-human Siah1 antibody (TransGenic Inc., Kumamoto, Japan), rabbit 
anti-human HIF1α antibody (H-206, Santa Cruz Biotechnology, Santa Cruz, CA), or mouse 
anti-LMP1 antibody (CS1-4, Dako) as the primary antibody. The sections were washed three times 
with phosphate-buffered saline (PBS, pH 7.2). After washing with PBS, the sections were exposed to 
Envision+ secondary antibody (Dako) for 30 minutes. The reaction products were developed by 
immersing the sections in a 3’3-diamidobenzidine tetrahydrochloride (DAB) solution. The sections 
were counterstained with methyl green or haematoxylin. 
 
2.3. In situ hybridization of EBV-encoded small RNA (EBER)  
In situ hybridization for the detection of EBV-encoded small RNA (EBER) was performed 
using EBER PNA probe/fluorescein and PNA ISH Detection kit (Dako) according to manufacturers’ 
instruction. Sections were counterstained with haematoxylin. 
 
2. 4. Evaluation of the specimens 
All slides were evaluated independently by two investigators (N. K. and S. K.) without 
previous knowledge of the clinical data and were then reviewed with the others. In each case, two 
arbitrary separate microscopic fields (200x) containing >200 tumour cells were evaluated. After 
counting both immunoreactive cells and the total number of tumour cells, the average frequency of 
immunoreactive cells was calculated. The average percentage of immunoreactive cells was defined 
as the expression score and was used for statistical analysis. In addition, the percentages of 
immunoreactive cells demonstrated a wide range of staining expression, (from 0 to 100%), and one 
peak for Siah1, HIF1α, and LMP1 expression demonstrated a frequency <10%. On the basis of these 
data, the cases were classified into negative and positive categories, as follows: negative, <10% 
immunoreactive cells; positive, ≥10% immunoreactive cells. EBER expression was qualitatively 
classified into either positive or negative. 
 
2. 5. Statistical Analysis 
IBM SPSS Statistics version 19 (IBM, Armonk, NY) was used for data analysis. The 
clinical characteristics of patients in relation to Siah1, HIF1α, and LMP1 expression were analysed 
using Fisher’s exact test and the chi-square test. The association between LMP1, Siah1, and HIF1α 
expression and the overall patient survival rates was analysed using Kaplan-Meier estimates and the 
log-rank test. Univariate and multivariate analysis were performed to identify prognostic factors 
associated with overall survival using Cox regression analysis. The relationships between the 
expression scores of Siah1, HIF1α, and LMP1 were analysed with Spearman’s rank correlation 
coefficient. P values of < 0.05 were considered statistically significant.  
 3. Results 
 
3.1. Immunostaining for Siah1, HIF1α, and LMP1 
The expression of Siah1, HIF1α, and LMP1 was examined by immunohistochemical 
staining in NPC biopsy specimens (Fig. 1A-C). The expression of these proteins was detected as 
dark brown staining. The expression of Siah1 revealed both cytoplasmic and nuclear localisation 
(Fig. 1A), whereas HIF1α was detected in the nucleus of the tumour cells (Fig. 1B). The mean 
expression scores for Siah1 and HIF1α were 12.23 ± 9.43% and 6.73 ± 5.74%, respectively. LMP1 
expression was noted to be most prominent in the membrane and cytoplasm of the tumour cells (Fig. 
1C). The mean LMP1 expression score was 12.46 ± 12.01%. Finally, of the 74 specimens, 30 cases 
(40.5%) were categorised as Siah1-positive, 27 cases (36.4%) were HIF1α-positive, and 35 cases 
(47.2%) were LMP1-positive. 
 
3.2. Expression of EBER 
In situ hybridization of EBER is considered the gold standard technique for detecting and 
localizing latent EBV in tissue samples in laboratory test [22]. EBER were detected in 62 of 74 cases. 
Positive hybridization signals were restricted to the nucleus of the tumour cells and were not 
observed in surrounding normal tissues or infiltrating lymphocytes (Fig. 1D). The expression of 
EBER was detected as blue staining. The expression of EBER was significantly correlated with 
histologic types. Of these 74 cases, 36 of 42 cases (85.7%) of non-keratinizing carcinoma (WHO 
type II) and all 26 cases (100%) of undifferentiated carcinoma (WHO type III) were EBER positive 
whereas 6 cases of squamous cell carcinoma (WHO type I) were negative (p = 0.02, Table 1). 
 
3.3. Association between Siah1, HIF1α, and LMP1 expression 
The relationship between Siah1, HIF1α, and LMP1 expression was statistically evaluated. 
There was a remarkable correlation between the expression of Siah1 and LMP1 (r = 0.57, p < 0.001, 
Fig. 2A), and a weak correlation between the expression of Siah1 and HIF1α (r = 0.33, p = 0.004, 
Fig. 2B). There was no significant relationship between the expression of HIF1α and LMP1 (r = 0.20, 
p = 0.09, Fig. 2C). 
 We also analysed relationship of Siah1, HIF1α, and LMP1 expression in EBER-positive 
NPC cases to clarify the contribution of LMP1 to the regulation of Siah1 and HIF1α was first found 
in EBV-expressing cell lines [16]. Of 62 EBER-positive cases, there was a remarkable correlation 
between the expression of Siah1 and LMP1 (r = 0.53, p < 0.001, data not shown), and a weak 
correlation between the expression of Siah1 and HIF1α (r = 0.38, p = 0.001, data not shown). 
Similarly, there was a weak relationship between the expression of HIF1α and LMP1 (r = 0.28, p = 
0.02, data not shown).  
 
3. 4. Relationship between clinicopathological features and the expression of Siah1 
The associations between the patients’ clinicopathological features and the expression 
score for Siah1, HIF1α, and LMP1 are shown in Table 1. Each TNM classification and stage 
grouping was divided into two categories [20], and the tumour stage was classified as “early” (T1 
and 2) or “advanced” (T3 and 4). The lesional lymph node stages were classified as lymph 
node-negative (N0) or lymph node-positive (N1, N2, or N3). Cases of distant metastasis at the initial 
visit were excluded in this study. Clinical stage was divided into “early” (I, II) and “advanced” (III, 
IV) categories. The Siah1 expression score was significantly associated with the progression of the 
tumour and the clinical stage (p = 0.001, p = 0.002, respectively). However, there was no significant 
relationship either the HIF1α or LMP1 expression scores and the clinicopathological features of the 
patients.  
 
3. 5. Patient prognosis and the expression of Siah1, HIF1α, and LMP1 
Next, we evaluated the prognostic value of Siah1, HIF1α, and LMP1 expression in patients 
with NPC. The patients with Siah1-positive tumours showed worse overall survival rates than those 
with Siah1-negative tumours (p = 0.017, Fig. 3A). Similarly, HIF1α-positive cases had worse 
prognosis than HIF1α-negative cases (Fig. 3B, p = 0.015). However, LMP1 expression had no 
influence on the prognosis (data not shown, p = 0.43). 
Finally, we evaluated whether Siah1 or HIF1α expression would represent an independent 
prognostic factor by Cox regression analysis. First, the association between the treatment protocol 
and patient prognosis was examined, and treatment differences were not shown to affect the 
prognosis of NPC patients, according to the results of a univariate analysis (p = 0.58, Table 2). 
Moreover, a univariate Cox regression analysis showed that age (≥50), gender (female), advanced 
tumour status (T3 + T4), and the advanced stage (III + IV), expression of Siah1, and HIF1α 
represented significant hazards (Table 2). Finally, a multivariate Cox regression analysis revealed 
that the expression of Siah1 and HIF1α, age (≥50), and advanced tumour stage (III + IV) were 




The current study showed that Siah1 expression was related to tumour progression in 
patients with NPC, whereas both HIF1α and LMP1 expression did not demonstrate such an 
association. The expression of HIF1α has previously been shown to be associated with a worse 
prognosis in nasopharyngeal carcinoma [8]. Here, we evaluated the prognostic role of Siah1 
expression in addition to HIF1α expression. A multivariate analysis revealed that Siah1 as well as 
HIF1α expression as an independent poor prognostic factors for patients with NPC (Table 2). Upon 
these findings, we speculate that downstream factors of Siah1 other than HIF1α may affect tumour 
progression. Siah was initially identified as a tumour suppressor gene [12], although recent studies 
have shown that knock-down of Siah by shRNA could significantly impede lung and pancreatic 
tumour growth in vitro and in vivo, indicating that expression of Siah itself promotes tumour growth 
[9, 13, 23]. Another study in breast cancer also showed that increased Siah expression was related to 
the aggressiveness of breast cancers [24]. Similarly, Siah1 nuclear expression was shown to be 
positively correlated with hepatocellular cancer progression [25]. These studies support our current 
results that Siah1 expression itself may influence the progression of NPC. Siah might serve a similar 
role as a downstream pathway component essential for oncogenic Ras signal as described in 
Drosophila [10, 26, 27]. Since Ras signal closely associated with cancer progression and 
transformation, such signal cascade may affect tumour progression by Siah1 as well as in human.  
Furthermore, we previously demonstrated that the expression of LMP1 significantly 
correlated with the expression of Siah1; moreover, LMP1 could stabilised Siah1 expression, 
resulting in HIF1α stabilisation in vitro [16]. In this study, the expression of LMP1 correlated with 
the expression of Siah1 in NPC biopsy specimens regardless of EBER (EBV) status. From these, 
Siah1 itself may play important role with tumour progression with or without EBV association. 
On the other hand, neither LMP1 nor Siah1 expression correlated with HIF1α expression 
in this study. Benders et al. reported a similar result and found that there was no significant 
relationship between the expression of LMP1 and HIF1α in 18 NPC biopsy specimens, as analysed 
by immunohistochemistry. They concluded that the regulation of HIF1α activity is dynamic and can 
change quickly due to variety of genetic/environmental stimuli. Thus, it is reasonable to speculate 
that, in addition to an LMP1-mediated pathway, HIF1α stabilisation may also be influenced by the 
local tumour environment, including tumour oxygen status, which has been shown to be a potent 
regulator of HIF1α. In our previous study, using cell culture system, HIF1α is up-regulated by Siah1 
through down-regulation of prolyl HIF-hydroxylase (PHD) 1 and 3 [16]. Thus, it is a matter of 
interest to examine the role of PHD in clinical NPC specimen. However, we could not have obtained 
proper antibodies for IHC. Thus, we would like to keep this issue as a future work.  
We also have reported that vascular endothelial growth factor (VEGF) could be an 
important regulator of angiogenesis in NPC tissue [28, 29, 30]. In addition to these studies, we 
reported LMP1 induces VEGF through HIF1α using epithelial cell lines [31]. Thus, the other factors 
related to hypoxic reaction may be of relevance to the gene examined in this study. The data 
presented here add more evidence that siah1, previously unexamined factor, is also involved in the 
malignant potential of NPC.  
In conclusion, the evaluation of Siah1 and HIF1α expression by immunohistochemistry 
may be valuable for identifying patients with NPC who are at a high risk for a poor outcome. 
Moreover, understanding the molecular mechanisms that regulate Siah expression will likely provide 
new insights into the pivotal function of Siah in cancer biology and should contribute to novel 
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Figure legends 
Fig. 1. (A) Immunostaining for seven-in-absentia homologue (Siah1) is shown. Dark brown staining 
indicates nuclear and cytoplasmic expression of Siah1 in patients with NPC. (B) Immunostaining for 
hypoxia-inducible factor 1 alpha (HIF1α) is shown. Dark brown staining indicates nuclear 
expression of HIF1α. (C) Immunostaining for latent membrane protein 1 (LMP1) is shown. LMP1 
protein was detected at the membrane, cytoplasm, and nucleus of tumour cells. Dark brown staining 
indicates nuclear expression of LMP1. (D) In situ hybridization with oligonucleotides probe to 
EBER. Positive reaction is observed in almost tumour cells not in lymphocytes. Blue staining 
indicates expression of EBER. Original magnification, 400x. 
Fig. 2. (A) Correlation between Siah1 and LMP1 expression in nasopharyngeal carcinoma. The 
Siah1 expression scores and the LMP1 expression scores for 74 NPC cases are plotted. Siah1 
expression demonstrated a significant correlation with LMP1 expression according to the Spearman 
correlation coefficient (r = 0.53, p < 0.001). (B) Correlation between Siah1 and HIF1α expression 
score in nasopharyngeal carcinoma. There was weak relationship between Siah1 and HIF1α 
expression score (r = 0.33, p = 0.004). (C) Correlation between LMP1 and HIF1α expression score 
in nasopharyngeal carcinoma. There was no significant relationship between LMP1 and HIF1α 
expression score (r = 0.26, p = 0.08). 
Fig. 3. Contribution of Siah1 (A) and HIF1α (B) expression to the survival of 74 patients with NPC. 
The relationship between Siah1 and HIF1α expression and patient prognosis was examined by 
Kaplan-Meier analysis.  
Table 1 
Relationship between the clinicopathological features of the patients and the expression of LMP1, Siah1, and HIF1α. 
                            
Variables             
Total number 
(n = 74) 
LMP1 (+) 












<50 y       
≥50 y      
Gender 
Female  
Male     
Histologic type (WHO) 
Squamous cell carcinoma (I)  
Nonkeratinizing carcinoma (II) 
Undifferentiated carcinoma (III) 
T classification 
T1 + T2 (early)                        
T3 + T4 (advanced)           
N classification 
N0 (negative) 
N1, 2, 3 (positive) 
Stage 
I + II (early)                 
III + IV (advanced)                   
Initial therapy 
ALa                      
CRb                                  
Rc   
EBER expression 
positive 




























11 (61.1)  
24 (42.8)   
 
10 (58.8) 
25 (43.8)   
 
 0 (0) 
22 (52.3) 
13 (50.0)  
 
10 (34.4) 
25 (55.5)   
 
10 (52.6) 
25 (45.4)   
 
 6 (31.5) 
29 (52.7)   
 
 3 (37.5) 
29 (49.1) 
 3 (42.8)   
 
35 (56.4) 




























 8 (44.4) 
22 (39.2)   
 
 8 (47.0) 
22 (38.5)   
 
 4 (66.6) 
17 (40.4) 
 9 (34.6)   
 
 5 (17.2) 
25 (55.5)   
 
11 (57.8) 
19 (34.5)   
 
 2 (10.5) 
28 (50.9)   
 
 5 (62.5) 
22 (37.3) 
 3 (42.8)   
 
25 (56.4)  




























 7 (38.8) 
20 (35.7)   
  
 5 (29.4) 
22 (38.5)   
 
 1 (16.6) 
18 (42.8) 
 8 (30.7)   
 
 7 (24.1) 
20 (44.4)   
 
 3 (15.7) 
24 (43.6)   
 
 4 (21.0) 
23 (41.8)   
 
 1 (12.5) 
23 (38.9) 
 3 (42.8)   
 
23 (37.0) 



























The values represent the numbers of patients; P values were generated by comparisons between the two groups. Tumour (T), node 
(N) classification, and overall stage were classified on the basis of the UICC classification, 1997. Histologic types were classified on 
the basis of the WHO criteria. aAlternating cisplatin-based chemoradiotherapy; bRadiation with concurrent cisplatin-based 
chemotherapy; cRadiation only. *Significant. 
Table 2  
Cox proportional hazard regression analysis of 74 nasopharyngeal carcinoma patients. 
 Univariate analysis Multivariate analysis 
Variables Hazard ratio (95% CI) P Hazard ratio (95% CI) P 
Age (≥50)   
Gender (female) 
Tumour (T3 + T4) 
Node (N positive)  
Stage (III + IV) 
Histologic type (II + III)                  
















































Factors with P values greater than 0.05 in the univariate models were not included (NI) in the multivariate analysis. aAlternating 
cisplatin-based chemoradiotherapy; bRadiation with concurrent cisplatin-based chemotherapy; cRadiation only.*Significant. 
Fig. 1. 
Fig. 2. 
Fig. 3. 
